Sector News

New GSK chairman backs CEO Witty to stay at helm

May 8, 2015
Life sciences
GlaxoSmithKline’s new chairman Philip Hampton has thrown his support behind the company’s current structure and chief executive despite pressure from some shareholders for a change.
 
In his first comments since becoming chairman at the conclusion of the drugmaker’s annual meeting on Thursday, Hampton told reporters he hoped that CEO Andrew Witty would continue to run GSK for a good length of time.
 
“Andrew has the complete support of the board. There are always shareholders who have points to make, but I certainly hope Andrew is here for a good while to come,” Hampton said.
 
He said there is no “hard and fast rule” about how long chief executives should serve.
 
Yet Hampton, also chairman of the Royal Bank of Scotland (RBS.L), said there is an issue about GSK’s relative performance in terms of shareholder returns.
 
“We haven’t kept up with some of the better-performing companies,” he said.
 
GSK shares have underperformed the European drugs sector .SXDP by 23 percent in the past year.
 
Hampton joined GSK’s board only after the company agreed a $20 billion-plus asset swap with Novartis (NOVN.VX) last year but said he “likes the mix now”.
 
POTENTIAL BREAK-UP?
 
Asked about the potential for a future break-up of GSK and spin-off of its consumer health division, Hampton said it was not obvious that such a move was warranted.
 
“To me, it isn’t a screaming case that this is a useless conglomerate that needs to be broken up,” he said. “There are absolutely good arguments for that (consumer) business to fit well with large pharma.”
 
Hampton said he was closely involved in Wednesday’s strategy presentation showcasing GSK’s new structure after the Novartis deal, particularly on the issue of protecting the company’s dividend for three years.
 
GSK’s 5 percent dividend yield is a major lure for investors, but several years of stagnant sales growth and stalling demand for its market-leading lung drugs have stretched its payout capacity.
 
Hampton said it is important to rebuild dividend cover, which would be done in part by the decision to scale back a planned one-off cash return to investors this year.
 
GSK is banking on consumer health and vaccines to help to deliver reliable long-term growth, while it is more wary than rivals about the ability of drugmakers to sustain current high prices for prescription drugs.
 
Hampton said this cautious stance made sense, given that current high valuations for early-stage drugs are viewed by many people as “a bit of a pharma market bubble”.
 
(Reporting by Ben Hirschler; Writing by Martinne Geller; Editing by David Goodman and David Evans)
 

comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach